annb0t
Top 20
Clinuvel Pharmaceuticals Limited
CLINUVEL Financial Performance CLINUVEL Group financial performance for the half year ended 30 December, since first commercial sales.
MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) --
Executive summary
Positive Results in the Half Year to 31 December 2022
19% increase in revenues from clinical demand for SCENESSE® (afamelanotide 16mg). 94% increase in NPAT; 67% increase in EBIT. Net assets increased by 11%; 16% growth in cash to $140.7 million sinc...
>>> Read more: Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
CLINUVEL Financial Performance CLINUVEL Group financial performance for the half year ended 30 December, since first commercial sales.
MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) --
Executive summary
Positive Results in the Half Year to 31 December 2022
19% increase in revenues from clinical demand for SCENESSE® (afamelanotide 16mg). 94% increase in NPAT; 67% increase in EBIT. Net assets increased by 11%; 16% growth in cash to $140.7 million sinc...
>>> Read more: Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
